A study published in the Annals of Internal Medicine suggests that women vaccinated against HPV should undergo less frequent cervical cancer screening.[1][2] For women vaccinated before age 25, only 2 or 3 screenings per lifetime are cost-effective, reducing unnecessary procedures without compromising cancer prevention.[1][2] The model considered vaccination age from 12 to 30 years, screening intervals and total number of tests, using Norwegian data.[1][2] Less frequent screening was better than the current recommendation of every 5 years for all age groups to be vaccinated.[1][2] The evaluation was based on a cost-effectiveness of $55,000 per quality-adjusted life-year.[1] For women vaccinated at the age of 25-30, screening every 10 years is sufficient.[2][5] The analysis supports adjusting vaccination age screening for better effectiveness and less harm.[1][2]